Insilico Medicine Scientists Propose Stricter Standards for Evaluating Generative AI-Produced Molecules

Insilico MedicineA new microperspective in the ACS journal Medicinal Chemistry Letters evaluates recent research on artificial intelligence (AI)-generated molecular structures from the point of view of the medicinal chemist and recommends guidelines for assessing the novelty and validity of these compounds. The perspective, published as part of the journal's virtual special issue "New Enabling Drug Discovery Technologies - Recent Progress," provides an analysis of eight molecular structures produced from generative chemistry published in the past two years to reveal the impact of AI and machine learning (ML) methods on modern-day drug discovery. In total, the authors found 55 recent publications covering generative chemistry efforts.

Designing synthetically feasible molecular structures that are novel and experimentally valid in the context of the disease is a challenge for generative chemistry algorithms. "We hoped to provide an in-depth analysis of the strengths of certain AI and ML generative chemistry approaches to produce truly novel and synthetically feasible molecular structures," says Alex Aliper, Ph.D., President of Insilico Medicine, who co-authored the study.

Rather than simply focusing on AI-generated structures, the authors examine the validity of these structures from the medicinal chemist's perspective - including synthesis and biological assessment.

Ultimately, say the Insilico scientists, as terms like "generative AI" and "generative chemistry" become more widespread, it’s essential to define relevant terms better and demonstrate the validity of generated structures across various measures. Their recommendations include:

  • Thoroughly inspecting generated structures in regards to their novelty and patentability.
  • Using rationally balanced preprocessing rules and medicinal chemistry filters adapted for generative pipelines.
  • Avoiding misleading statements, especially “novel drug candidate” and “novel lead compounds,” which must be supported with exhaustive biological data. In many cases, “primarily hit compound” is the only term that can be reasonably applied for active compounds of generative origin.
  • Employing severe similarity metrics.
  • Providing medicinal chemists with all generated structures besides those presented by authors as the most promising ones.
  • Evaluating active molecules of AI origin at least using standard MTS or MTT assays to avoid nonspecific action and cytotoxicity.
  • Assessing synthetic accessibility.
  • Improving the generative engine, with more attention to the training set, the test set, and similarity metrics.
  • Paying more attention to reinforcement learning with advanced systems and processes intended to rapidly evaluate the generated molecules for desired properties.

"We are encouraged by the increasing use of generative AI in chemistry which can help speed and expand drug discovery efforts," says Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine and co-author of the paper. "But we believe that publications in generative chemistry should always include experimental validation and rigorous evaluation and review by medicinal chemists. We think the process can be further improved by introducing new techniques to generate and evaluate the novel molecular structures from a medicinal chemistry perspective to produce the next generation of novel AI-generated drugs."

About Insilico Medicine

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.

Ivanenkov Y, Zagribelnyy B, Malyshev A, Evteev S, Terentiev V, Kamya P, Bezrukov D, Aliper A, Ren F, Zhavoronkov A.
The Hitchhiker's Guide to Deep Learning Driven Generative Chemistry.
ACS Med Chem Lett. 2023 Jun 30;14(7):901-915. doi: 10.1021/acsmedchemlett.3c00041

Most Popular Now

AI also Assesses Dutch Mammograms Better…

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by...

RSNA AI Challenge Models can Independent…

Algorithms submitted for an AI Challenge hosted by the Radiological Society of North America (RSNA) have shown excellent performance for detecting breast cancers on mammography images, increasing screening sensitivity while...

AI could Help Emergency Rooms Predict Ad…

Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study by the...

Head-to-Head Against AI, Pharmacy Studen…

Students pursuing a Doctor of Pharmacy degree routinely take - and pass - rigorous exams to prove competency in several areas. Can ChatGPT accurately answer the same questions? A new...

NHS Active 10 Walking Tracker Users are …

Users of the NHS Active 10 app, designed to encourage people to become more active, immediately increased their amount of brisk and non-brisk walking upon using the app, according to...

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...